I

f you bought a single share of AnaptysBio when it went public, you’d have more than quintupled your money by now. If you did the same with Zymeworks at its IPO, you’d be out five bucks.

Those were the respective best and worst performers among 2017’s 40 biotech IPOs. As of late December, the class is doing well across the board, with an average return of more than 40 percent. Remove the outliers — like AnaptysBio’s 528 percent gain and Argenx’s 240 percent jump — and the median 2017 IPO is up about 12 percent.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy